IL1beta抗体—艾普蒂

+ +

•  

   

     Western blot analysis of IL1 beta expression in RAW 264.7 cell treated with Lipopolysaccharide (LPS) cell lysate.    

  
  

Interleukin-1 beta (IL-1β) is a pro-inflammatory cytokine central to innate immune responses, primarily produced by macrophages, monocytes, and dendritic cells. It plays a key role in mediating inflammation, fever, and tissue damage during infections, autoimmune diseases, and stress. Dysregulated IL-1β signaling is implicated in chronic inflammatory conditions like rheumatoid arthritis, gout, atherosclerosis, and type 2 diabetes, as well as autoinflammatory syndromes such as cryopyrin-associated periodic syndromes (CAPS).

IL-1β antibodies are therapeutic or research tools designed to neutralize IL-1β activity by blocking its interaction with the IL-1 receptor (IL-1R). Monoclonal antibodies like canakinumab (a human IgG1 anti-IL-1β antibody) have been clinically approved to treat CAPS, gout, and cardiovascular inflammation. These antibodies bind IL-1β with high specificity, preventing its pro-inflammatory effects and downstream signaling pathways (e.g., NF-κB activation).

Research-grade IL-1β antibodies are widely used in immunoassays (ELISA, Western blot), immunohistochemistry, and functional studies to elucidate IL-1β's role in disease mechanisms. The development of IL-1β-targeted therapies highlights its pathological significance, offering insights into cytokine-driven inflammation and validating IL-1β as a therapeutic target. However, long-term immunosuppression risks, such as increased infection susceptibility, necessitate careful clinical evaluation. Overall, IL-1β antibodies remain pivotal in both translational research and precision medicine for inflammatory disorders.